CRISPR THERAPEUTICS AG
Assets & Liabilities
| Period | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| Dec 2013 | — | — | $361.0K |
| Dec 2014 | — | — | $945.0K |
| Sep 2015 | — | — | $49.0M |
| Dec 2015 | $124.0M | $159.4M | $156.0M |
| Mar 2016 | — | — | $200.6M |
| Jun 2016 | — | — | $246.8M |
| Sep 2016 | $155.6M | $278.7M | $228.6M |
| Dec 2016 | $112.1M | $345.0M | $315.5M |
| Mar 2017 | $107.2M | $322.3M | $288.9M |
| Jun 2017 | $107.2M | $305.0M | $272.3M |
| Sep 2017 | $103.4M | $282.3M | $253.5M |
| Dec 2017 | $83.5M | $271.3M | $239.8M |
| Mar 2018 | $84.1M | $374.5M | $341.8M |
| Jun 2018 | $88.0M | $353.1M | $319.7M |
| Sep 2018 | $101.6M | $518.9M | $487.3M |
| Dec 2018 | $96.8M | $489.0M | $456.6M |
| Mar 2019 | $118.1M | $497.9M | $437.5M |
| Jun 2019 | $126.6M | $494.2M | $427.9M |
| Sep 2019 | $128.7M | $720.6M | $629.7M |
| Dec 2019 | $127.3M | $1.07B | $943.8M |
| Mar 2020 | $121.2M | $1.01B | $889.7M |
| Jun 2020 | $135.9M | $1.05B | $945.1M |
| Sep 2020 | $141.7M | $1.49B | $1.04B |
| Dec 2020 | $163.7M | $1.83B | $1.17B |
| Mar 2021 | $152.4M | $1.96B | $1.13B |
| Jun 2021 | $295.7M | $2.90B | $1.65B |
| Sep 2021 | $308.8M | $2.82B | $1.01B |
| Dec 2021 | $352.4M | $2.75B | $923.0M |
| Mar 2022 | $361.3M | $2.61B | $683.9M |
| Jun 2022 | $372.5M | $2.46B | $496.9M |
| Sep 2022 | $399.4M | $2.35B | $494.2M |
| Dec 2022 | $367.6M | $2.24B | $211.9M |
| Mar 2023 | $389.5M | $2.24B | $344.4M |
| Jun 2023 | $381.0M | $2.20B | $444.8M |
| Sep 2023 | $359.0M | $2.09B | $527.8M |
| Dec 2023 | $346.8M | $2.23B | $389.5M |
| Mar 2024 | $355.1M | $2.44B | $707.4M |
| Jun 2024 | $358.9M | $2.34B | $484.5M |
| Sep 2024 | $316.5M | $2.26B | $225.7M |
| Dec 2024 | $310.0M | $2.24B | $298.3M |
| Mar 2025 | $336.9M | $2.17B | $235.2M |
| Jun 2025 | $318.6M | $2.03B | $193.6M |
| Sep 2025 | $329.3M | $2.25B | $286.5M |
| Dec 2025 | $343.4M | $2.27B | $347.6M |
| Mar 2026 | $911.3M | $2.73B | $423.3M |
| Jun 2026 | $904.2M | $2.65B | $291.3M |